FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3210442014> ?p ?o ?g. }

• W3210442014 endingPage "4122" @default.
• W3210442014 startingPage "4121" @default.
• W3210442014 abstract "At the 2021 annual meeting of the American Society of Clinical Oncology, positive data from several phase 3 clinical trials indicated an earlier role for novel therapeutic treatments for patients with metastatic disease. The studies suggest that adjuvant therapy with newer agents may increase disease-free survival in a range of tumor types and benefit select subsets of patients with a higher risk of recurrence after primary treatment. The results of 4 clinical trials in total were presented; they investigated adjuvant treatment versus placebo or best supportive care in resected renal cell carcinoma, locally advanced cervical cancer, early-stage non–small cell lung cancer (NSCLC), and BRCA1/2-mutant, HER2-negative early breast cancer.1 Among the trials that were presented, data from the OlympiA trial (ClinicalTrials.gov identifier NCT02032823) regarding the use of olaparib (Lynparza), a poly(adenosine diphosphate ribose) polymerase inhibitor, revealed that the invasive (3-year) diseasefree survival rate improved to 85.9% (in contrast to 77.1% with a placebo) for patients with HER2-negative breast cancer and a BRCA1/2 mutation present (hazard ratio [HR] 0.58; 99.5% CI, 0.41-0.82; P < 0.0001). These patients were considered to have a high risk of recurrence after initial local treatment and neoadjuvant/adjuvant therapy.1, 2 The KEYNOTE-564 trial (ClinicalTrials.gov identifier NCT03142334) showed an estimated disease-free survival rate of 77.3% with the use of pembrolizumab (Keytruda), a PD-1 inhibitor (in contrast to 68.1% with a placebo), in patients with clear cell renal cell carcinoma. The patients studied were categorized as intermediate high risk or high risk for recurrence after nephrectomy. A trend suggesting a 96.6% overall survival benefit with pembrolizumab versus a placebo (93.5%) was also noted by investigators.1, 3 Negative trial data from patients with advanced cervical cancer and a high rate of potential relapse were also discussed during the plenary session. Data from the OUTBACK trial (ACTRN12610000732088) illustrated similar progressionfree survival rates (63% vs 61%; 95% CI, -5 to +9; P = 0.61) without improved overall survival (72% vs 71%; 95% CI, -6 to +7; P = 0.91) at 5 years for patients with advanced cervical cancer who were given adjuvant chemotherapy after the administration of cisplatin-based chemoradiation.1, 4 IMpower010 (ClinicalTrials.gov identifier NCT02486718), a randomized, global, open-label trial of atezolizumab (Tecentriq), an anti–PD-L1, versus best supportive care after adjuvant treatment, studied patients with resected stage IB to IIIA NSCLC. A total of 1280 patients were enrolled; they received 4 cycles of cisplatin with vinorelbine, docetaxel, pemetrexed, or gemcitabine. Patients were randomized to receive 16 cycles of atezolizumab every 3 weeks or best supportive care. Those enrolled in the atezolizumab arm were given a median of 16 doses with periodic radiologic imaging; cycles in both phases lasted for 21 days.5 The primary results of the IMpower010 study illustrated a disease-free survival benefit with adjuvant atezolizumab after adjuvant chemotherapy in the PD-L1 TC ≥1% stage II-IIIA (stratified HR 0.66; P = 0.0039) and all randomized stage II-IIIA populations (stratified HR 0.79; P = 0.0205). Although adverse events of any grade occurred in 92.7% of the patients in the atezolizumab arm, the discontinuation rate in this population was 18.2%, and the safety profile was similar to that of prior use of atezolizumab as a monotherapy. Specific adverse events were not detailed in the published abstract results.5 Suresh S. Ramalingam, MD, of the Winship Cancer Institute at Emory University in Atlanta, Georgia, gave a virtual interview to CancerNetwork (https://www.cancernetwork.com/) related to the American Society of Clinical Oncology plenary session. “The notion that we could use immune checkpoint inhibitors in early-stage disease to improve overall outcomes is very exciting and an important step forward in the management of early-stage lung cancer.” —Suresh S. Ramalingam, MD Conversely, tailoring treatment interventions in the adjuvant setting may also dictate that some patients will do best by avoiding more toxic treatments. Placing an emphasis on improved outcomes for patients who face a possibly increased residual risk after their initial treatment highlights the importance of the comprehensive selection and strategy of therapy in the adjuvant care setting." @default.
• W3210442014 created "2021-11-08" @default.
• W3210442014 creator A5023588281 @default.
• W3210442014 date "2021-10-29" @default.
• W3210442014 modified "2023-09-24" @default.
• W3210442014 title "Adjuvant trials suggest changes to non–small cell lung cancer treatment paradigm" @default.
• W3210442014 cites W3165887339 @default.
• W3210442014 cites W3166483804 @default.
• W3210442014 cites W3167153458 @default.
• W3210442014 cites W3167171623 @default.
• W3210442014 doi "https://doi.org/10.1002/cncr.33970" @default.
• W3210442014 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34714932" @default.
• W3210442014 hasPublicationYear "2021" @default.
• W3210442014 type Work @default.
• W3210442014 sameAs 3210442014 @default.
• W3210442014 citedByCount "0" @default.
• W3210442014 crossrefType "journal-article" @default.
• W3210442014 hasAuthorship W3210442014A5023588281 @default.
• W3210442014 hasBestOaLocation W32104420141 @default.
• W3210442014 hasConcept C121608353 @default.
• W3210442014 hasConcept C126322002 @default.
• W3210442014 hasConcept C141071460 @default.
• W3210442014 hasConcept C142724271 @default.
• W3210442014 hasConcept C143998085 @default.
• W3210442014 hasConcept C204787440 @default.
• W3210442014 hasConcept C207103383 @default.
• W3210442014 hasConcept C27081682 @default.
• W3210442014 hasConcept C2776256026 @default.
• W3210442014 hasConcept C2777701055 @default.
• W3210442014 hasConcept C2777863537 @default.
• W3210442014 hasConcept C2777982462 @default.
• W3210442014 hasConcept C2780057760 @default.
• W3210442014 hasConcept C44249647 @default.
• W3210442014 hasConcept C530470458 @default.
• W3210442014 hasConcept C535046627 @default.
• W3210442014 hasConcept C71924100 @default.
• W3210442014 hasConceptScore W3210442014C121608353 @default.
• W3210442014 hasConceptScore W3210442014C126322002 @default.
• W3210442014 hasConceptScore W3210442014C141071460 @default.
• W3210442014 hasConceptScore W3210442014C142724271 @default.
• W3210442014 hasConceptScore W3210442014C143998085 @default.
• W3210442014 hasConceptScore W3210442014C204787440 @default.
• W3210442014 hasConceptScore W3210442014C207103383 @default.
• W3210442014 hasConceptScore W3210442014C27081682 @default.
• W3210442014 hasConceptScore W3210442014C2776256026 @default.
• W3210442014 hasConceptScore W3210442014C2777701055 @default.
• W3210442014 hasConceptScore W3210442014C2777863537 @default.
• W3210442014 hasConceptScore W3210442014C2777982462 @default.
• W3210442014 hasConceptScore W3210442014C2780057760 @default.
• W3210442014 hasConceptScore W3210442014C44249647 @default.
• W3210442014 hasConceptScore W3210442014C530470458 @default.
• W3210442014 hasConceptScore W3210442014C535046627 @default.
• W3210442014 hasConceptScore W3210442014C71924100 @default.
• W3210442014 hasIssue "22" @default.
• W3210442014 hasLocation W32104420141 @default.
• W3210442014 hasLocation W32104420142 @default.
• W3210442014 hasOpenAccess W3210442014 @default.
• W3210442014 hasPrimaryLocation W32104420141 @default.
• W3210442014 hasRelatedWork W2054423421 @default.
• W3210442014 hasRelatedWork W2148741545 @default.
• W3210442014 hasRelatedWork W2224319365 @default.
• W3210442014 hasRelatedWork W2340130805 @default.
• W3210442014 hasRelatedWork W3045341250 @default.
• W3210442014 hasRelatedWork W3170185633 @default.
• W3210442014 hasRelatedWork W4220709271 @default.
• W3210442014 hasRelatedWork W4220803681 @default.
• W3210442014 hasRelatedWork W4225126402 @default.
• W3210442014 hasRelatedWork W4249565876 @default.
• W3210442014 hasVolume "127" @default.
• W3210442014 isParatext "false" @default.
• W3210442014 isRetracted "false" @default.
• W3210442014 magId "3210442014" @default.
• W3210442014 workType "article" @default.